Upadacitinib hemihydrate
- CAS NO.：2050057-56-0
- Empirical Formula: C17H21F3N6O2
- Molecular Weight: 398.39
- Update Date: 2024-08-12 17:17:06
What is Upadacitinib hemihydrate?
Clinical Use
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Each prolonged-release tablet (RINVOQ 15 mg prolonged-release tablets.) contains upadacitinib hemihydrate, equivalent to 15 mg of upadacitinib.
Properties of Upadacitinib hemihydrate
Safety information for Upadacitinib hemihydrate
Computed Descriptors for Upadacitinib hemihydrate
| InChIKey | VJSRYIXHEWRBKD-NFGOAHBONA-N |
| SMILES | C([C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2C=NC3NC=CC=3N12)C.O |&1:1,13,r| |
Abamectin manufacturer
Svak Life Sciences
1Y
Phone:+91-9705383777
Whatsapp: +91 9705383777
product: 2050057-56-0 Upadacitinib hemihydrate 98%
You may like
-
2050057-56-0 Upadacitinib hemihydrate 98%View Details
2050057-56-0 -
77-92-9 99%View Details
77-92-9 -
77-92-9 99%View Details
77-92-9 -
8000-27-9 CEDAR WOOD OIL 99%View Details
8000-27-9 -
AMMONIUM DICHROMATE 7789-09-5 99%View Details
7789-09-5 -
77-78-1 DIMETHYL SULPHATE 99%View Details
77-78-1 -
7778-80-5 POTASSIUM SULPHATE 99%View Details
7778-80-5 -
95-54-5 99%View Details
95-54-5
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.